Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444203) titled 'Transformative Research in Diabetic Nephropathy 2.0' on Feb. 24.
Study Type: Observational
Primary Sponsor: University of Pennsylvania
Condition:
Diabetic Nephropathies
Kidney Diseases
Renal Insufficiency, Chronic
Diabetes Mellitus, Type 2
Intervention:
Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Drug: Renin-angiotensin-aldosterone system blockade
Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Recruitment Status: Recruiting
Date of First Enrollment: November 12, 2025
Target Sample Size: 200
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/stu...